Abbott Laboratories Receives FDA Approval to Include Interactive Features in CardioMEMS Heart Monitor
MT newswire2026/10/05 13:5809:58 AM EDT, 10/05/2026 (MT Newswires) -- Abbott Laboratories (ABT) said Monday that it has received US Food and Drug Administration approval for technology that provides updates directly to patients through its CardioMEMS HF System. The company said the technology allows doctors to share daily heart pressure readings directly with patients between office visits. It said the technology also provides the ability to send medication adjustment instructions to patients' smartphones and measures pressure through an implanted sensor in the pulmonary artery. Abbott said it plans to make CardioGuide HF App and Dynamic Treatment Plan available later in the year. Price: 97.69, Change: +0.19, Percent Change: +0.19
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
About 700,000 BTC have flowed out of exchanges in the past year.
Korean retail investors shift to the US in Q3: Sold over 5.5 trillion won of Korean stocks, purchased more than 10 trillion won of US stocks
In the third quarter, Korean retail investors made net purchases of US stocks worth approximately 10.15 trillion won, marking a complete reversal from the previous pattern in the first half of the year, when they made net purchases of nearly 100 trillion won in KOSPI stocks. In September alone, the sell-off amount reached as high as 14.2 trillion won. Analysts attribute this shift to a combination of factors: a sharp decline in KOSPI at high levels, the continued strength of the US stock market driven by AI themes, and the appreciation of the Korean won reducing currency exchange costs.
Copper prices approach historic highs! UBS remains bullish: "Still most optimistic"
Crypto prices
More
